Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Idarubicin 10mg capsules
0801020P0AAADAD
|
Idarubicin hydrochloride | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Idarubicin 10mg powder for solution for injection vials
0801020P0AAABAB
|
Idarubicin hydrochloride | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Idarubicin 10mg/10ml solution for injection vials
0801020P0AAAFAF
|
Idarubicin hydrochloride | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Idarubicin 25mg capsules
0801020P0AAAEAE
|
Idarubicin hydrochloride | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Idarubicin 5mg capsules
0801020P0AAACAC
|
Idarubicin hydrochloride | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Idarubicin 5mg powder for solution for injection vials
0801020P0AAAAAA
|
Idarubicin hydrochloride | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Idarubicin 5mg/5ml solution for injection vials
0801020P0AAAGAG
|
Idarubicin hydrochloride | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Zavedos 10mg capsules
0801020P0BBACAD
|
Zavedos | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Zavedos 10mg powder for solution for injection vials
0801020P0BBABAB
|
Zavedos | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Zavedos 10mg/10ml solution for injection vials
0801020P0BBAGAF
|
Zavedos | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Zavedos 25mg capsules
0801020P0BBADAE
|
Zavedos | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Zavedos 5mg capsules
0801020P0BBAEAC
|
Zavedos | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Zavedos 5mg powder for solution for injection vials
0801020P0BBAAAA
|
Zavedos | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Zavedos 5mg/5ml solution for injection vials
0801020P0BBAFAG
|
Zavedos | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.